Usage of lipid-lowering drugs such as atorvastatin and rosuvastatin in the management of hyperlipidemia in multiple vessel wall block patients
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20175688Keywords:
Atorvastatin, Coronary angioplasty LDL, Dyslipidemia, HDL, Multiple vessel blocks, RosuvastatinAbstract
Background: Multi-vessel coronary artery disease (CAD) is a disease stage in which at least two or three of the epicardial coronary arteries is involved with atherosclerosis of significant severity. The multi-vessel disease is often associated with a higher burden of comorbidities, left ventricular dysfunction, and cardiovascular risk. Dyslipidaemia is the commonest cause of the blood vessel diseases and their incidence has been rising all over the world thereby increasing the morbidity and mortality due to cardiovascular diseases. Dyslipidaemia is also one of the component of metabolic syndrome along with another group of cardiovascular risk factors such as high blood pressure (BP), abdominal obesity, and insulin intolerance, whose concurrent appearance increases the risk of atherosclerotic cardiovascular disease. To compare the efficacy of atorvastatin and rosuvastatin in the management of hyperlipidaemia. To compare the dose-related efficacy of statins on lipid goal achievement in patients with hyperlipidaemia.
Methods: This prospective, randomized, single-blinded interventional study was conducted for a period of 1 year [2014-1015] in medicine OPD in Rajah Muthiah Medical College and Hospital. A total number of 100 patients with diagnosed multiple vessel blocks were included in this study. Among them, 50 patients were randomized to group A. 50 patients were selected to group B. 50 patients of the group A are treated with Atorvastatin up 10 mg once daily for 8 weeks. 50 patients of group B were treated with Rosuvastatin up to 10mg/day. For 8 weeks the results were analysed accordingly.
Results: Even though both rosuvastatin 10mg/day and atorvastatin 10mg/day produced a reduction in total cholesterol (p<0.001) significantly, rosuvastatin produced a reduction in LDL levels (p<0.001) more significantly than atorvastatin 10mg/day.
Conclusions: Rosuvastatin produces a greater reduction in serum LDL-C levels and should, therefore, be preferred over atorvastatin. Both the treatment regimens significantly decreased TC, TG, LDL C, VLDL C, but the reduction was more and statistically significant in Rosuvastatin when compared with atorvastatin-treated group at the end of 8 weeks.
References
Athyros VG, Papageorgiou AA, Athyrou VV, Dimitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabet Care. 2002;25(7):1198-202.
Bakker-Arkema RG, Davidson MH, Goldstein RJ, Davignon J, Isaacsohn JL, Weiss SR et al. Efficacy and safety of a new HMG-CoA reductase inhibitor, atorvastatin, in patients with hypertriglyceridemia. JAMA. 1996;275(2):128-33.
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Eng J Med. 2004;350(15):1495-504.
M McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr Med Res Opin. 2003;19(8):689-98.
Fiévet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Current opinion in lipidology. 2009;20(6):505.
Kwang KK, Michael JQ, Seung HH, Wook-Jin C, Jeong YA, Yield-Hea S, et al. Additive Beneficial Effects of Fenofibrate Combined with Atorvastatin in the Treatment of Combined Hyperlipidemia. Am J Cardiol. 2005;45(10):1649-53.
Athyros VG, Papageorgiou AA, Hatzikonstandinou HA, Didangelos TP, Carina MV, Kranitsas DF et al. Safety and efficacy of long-term statin-fibrate combinations in patients with refractory familial combined hyperlipidemia. Am J Cardiol. 1997;80(5):608-13.
Blake GJ, Otvos JD, Rifai N, Ridker PM.Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women. Circulation. 2002;106:1930-7.
Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). Am J Cardiol. 2003;92:152-60.
Hedman M, Matikainen T, Fohr A. Efficacy and safety of pravastatin in children and adolescents with heterozygous familial hypercholesterolemia: A prospective clinical follow-up study. J Clin Endocrinol Metab. 2005;90:1942-52.
Cromwell WC, Otvos JD, Keyes MJ, PencinaMJ, Sullivan L, Vasan RS, Wilson PW, et al. LDL particle number and risk of future cardiovascular disease in the Framingham offspring study implications for LDL management. J Clin Lipidol. 2007;1:583-92.
Downs JR, Clearfield M, Weis S. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA. 1998;279:1615-22.
Fiévet C, Staels B. Combination therapy of statins and fibrates in the management of cardiovascular risk. Current Opinion in Lipidology. 2009;20(6):505-11.
Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidemia to reduce coronary risk. J Cardiovasc Risk. 2003;10:121-8.
Judith M.E. drug treatment of hyperlipidemia in women. JAMA. 2004:291(18):2243-52.
Kathiresan S, Otvos JD, Sullivan LM, Keyes MJ, Schaefer EJ, Wilson PW, et al. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study. Circulation. 2006;113:20-9.
Kurtosis DN, Millions H, Bairaktari E, Elisaf MS. Efficacy of a combination of atorvastatin and micronized fenofibrate in the treatment of severely mixed hyperlipidemia. Eur J Clin Pharmacol. 2000;56(9-10):631-5.
